Carole R. Berini, PhD, and Saamir Pasha, MPH, of Ontada discuss a model designed to estimate missing baseline ECOG performance status in advanced prostate cancer and the validation needed before it can support broader real-world evidence research.
|Articles|May 16, 2022
Daily Medication Pearl: Atezolizumab (Tecentriq)
Author(s)Saro Arakelians, PharmD
Atezolizumab (Tecentriq) is indicated for use in urothelial carcinoma, non-small cell lung cancer, triple-negative breast cancer, small cell lung cancer, hepatocellular carcinoma, and melanoma.
Advertisement
Medication Pearl of the Day: Atezolizumab (Tecentriq)
Indication: Atezolizumab (Tecentriq) is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for use in urothelial carcinoma, non-small cell lung cancer, triple-negative breast cancer, small cell lung cancer, hepatocellular carcinoma, and melanoma.
Insight:
- Dosing:Administer atezolizumab intravenously over 60 minutes. If the first infusion is tolerated, all subsequent infusions may be delivered over 30 minutes.
- Dosage forms: Injection: 840 mg/14 mL (60 mg/mL) and 1200 mg/20 mL (60 mg/mL) solution in a single-dose vial.
- Adverse events:Most common adverse reactions (≥ 20%) with atezolizumab as a single agent were fatigue/asthenia, decreased appetite, nausea, cough, and dyspnea.
- Mechanism of action: PD-L1 may be expressed on tumor cells and/or tumor infiltrating immune cells and can contribute to the inhibition of the anti-tumor immune response in the tumor microenvironment. Binding of PD-L1 to the PD-1 and B7.1 receptors found on T cells and antigen presenting cells suppresses cytotoxic T-cell activity, T-cell proliferation and cytokine production
- Manufacturer: Genentech
Source
Advertisement
Related to this article
Thomas Hope, MD, explains why radioligand therapies should be evaluated according to whether their clinical benefits outweigh their risks within the context of patients’ available cancer treatment options.
The randomized ALLIANCE A051701 trial closed early when treatment-related toxicity and mortality were increased without improving PFS in patients with newly diagnosed double-hit lymphoma.
Robin Tumlinson, PharmD, BCOP, discusses how rapidly expanding bladder cancer options are creating new questions around treatment sequencing, toxicity management, biomarker testing, and multidisciplinary care.
A prospective observational study found microplastics more frequently and at higher levels in lung samples from patients with lung malignancies, although the findings do not establish that the particles cause cancer.
Helicobacter pylori exposure could be associated with approximately 22% of colorectal cancer cases worldwide.
Eight-year phase 3 ADAURA trial data show adjuvant osimertinib boosts survival in patients with resected EGFR-mutant NSCLC.
Machine-learning and multiple-imputation models could help researchers estimate missing baseline Eastern Cooperative Oncology Group performance status in advanced prostate cancer.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Adult Pneumococcal Immunizations: A Practical Guide for Pharmacists
2
FDA Approves Rebisufligene Etisparvovec as First Gene Therapy for Children With Sanfilippo Syndrome Type A
3
How Pharmacists Overcome PCSK9 Inhibitor Access Barriers
4
Finerenone Receives FDA Approval for Treatment of Adults With CKD Associated With T1D
5